BIAF — bioAffinity Technologies, Inc. Company Overview

Executive Summary

bioAffinity Technologies, Inc. (NASDAQ: BIAF) is a San Antonio, Texas-based diagnostics company commercializing CyPath® Lung, a noninvasive flow-cytometry-and-AI-based test designed to help physicians distinguish malignant from benign indeterminate pulmonary nodules found on CT scans. The company operates through two wholly owned subsidiaries: Precision Pathology Laboratory Services (PPLS), a CAP-accredited, CLIA-certified clinical laboratory that runs the test, and OncoSelect Therapeutics, an early-stage siRNA therapeutics research effort. bioAffinity is a small-cap, cash-constrained commercial-stage diagnostics company: for fiscal 2025 it reported total consolidated revenue of $6.2 million (down 34% year over year following the deliberate wind-down of an unprofitable legacy pathology-services line) even as CyPath Lung-specific revenue grew 87% to $963,000 on more than 1,200 delivered test results. As of mid-2026 the company's market capitalization had fallen to roughly $2.8-3 million, reflecting a market that remains skeptical of its path to scale and profitability.

Core Business Model

bioAffinity's core model pairs a proprietary diagnostic technology (CyPath Lung) with an owned clinical laboratory (PPLS) that performs the test as a Laboratory Developed Test (LDT), billing physicians, health systems and payers (including Medicare via a dedicated CPT code, 0406U, effective January 2024) on a per-test basis. This vertically integrated lab-plus-test model lets the company control quality and capture the full economics of each test rather than licensing the assay to third-party labs, but it also means growth is gated by the company's own sales/marketing reach and by payer coverage decisions rather than by a broader distributed-lab network.

Business Segments

The company is effectively organized around two activities: (1) diagnostics — CyPath Lung and pipeline companion-diagnostic tests for asthma/COPD run through PPLS, which is the current and near-term revenue driver; and (2) therapeutics — OncoSelect Therapeutics, a nascent, non-revenue-generating research program exploring siRNA-based treatments targeting CD320 and LRP2 receptors for topical squamous cell skin cancer. The legacy general pathology services business that PPLS previously ran was intentionally discontinued in 2025 because it was unprofitable, which explains the divergence between shrinking total revenue and growing CyPath-specific revenue.

Product Portfolio

CyPath Lung is the flagship product: patients self-collect a sputum sample at home using an FDA-cleared Acapella Choice Blue device, ship it overnight to PPLS, and receive results within three days. The test uses a synthetic porphyrin compound (TCPP) that selectively fluoresces in cancer-associated cells, combined with flow cytometry and a proprietary machine-learning analysis pipeline, to avoid operator subjectivity. Peer-reviewed clinical data (Respiratory Research, January 2023) showed 92% sensitivity, 87% specificity and 88% accuracy for nodules under 20mm — a "balanced" profile the company positions against rivals that trade off sensitivity for specificity or vice versa. Beyond lung cancer, the company is developing flow-cytometry-based companion diagnostics to identify asthma/COPD patients most likely to respond to biologics such as dupilumab and benralizumab, and, through OncoSelect, an early-stage siRNA oncology therapeutic pipeline.

Competitive Landscape

CyPath Lung competes in the fast-growing pulmonary nodule risk-stratification market against several venture- and public-company-backed rivals: LungLife AI's LungLB (77% sensitivity / 72% specificity, per bioAffinity's own comparison), Biodesix's Nodify XL2/CDT rule-in/rule-out tests, and Veracyte's Percepta Nasal Swab RNA classifier (which the company notes classifies nearly half of patients as "intermediate risk," limiting clinical utility). bioAffinity argues its combined high sensitivity and specificity, noninvasive at-home collection, and relatively low cost differentiate CyPath Lung from these alternatives. The company also references low-dose CT screening's poor positive predictive value (~4%) as the core clinical problem CyPath Lung is designed to solve by reducing unnecessary invasive biopsies. Regulatory tailwinds returned in 2025: after the FDA's May 2024 rule asserting device jurisdiction over LDTs was vacated by a federal court (March 2025) and formally rescinded by FDA (September 2025), CyPath Lung's LDT commercial pathway was reaffirmed without new FDA clearance requirements.

Strategic Strengths & Risks

Strengths include a differentiated, peer-reviewed-validated core technology with a genuinely balanced sensitivity/specificity profile, a defensible IP position (19 issued U.S. and international patents as of year-end 2025, with expirations out to 2042), Medicare reimbursement coverage via a dedicated CPT code, and a large and growing addressable market (indeterminate pulmonary nodules are projected to grow from 2.9 million cases in 2025 to 4.7 million by 2030, a $4.7 billion opportunity, plus an $870 million cancer-survivor surveillance market). Risks are severe and typical of a micro-cap diagnostics company: persistent net losses and cash burn (analysts have flagged cash-burn concerns), a market cap that has fallen roughly 69% over the trailing year to near $3 million, reliance on continued equity raises ($16.9 million raised in 2025 alone) that create material dilution risk, a still-small revenue base (under $1 million from CyPath specifically) relative to fixed lab and commercial infrastructure costs, and the ever-present regulatory risk that FDA could revisit LDT oversight in the future. Physician and payer adoption also remains an execution risk that will determine whether CyPath Lung reaches meaningful scale.

Financial Overview

Fiscal 2025 consolidated revenue was $6.2 million, down 34% from the prior year due to the deliberate exit from unprofitable legacy pathology services, while CyPath Lung-specific revenue rose 87% to $963,000 (from $516,000 in 2024) on more than 1,200 tests delivered. The company raised approximately $16.9 million in gross proceeds from equity offerings during 2025 to fund operations, underscoring continued reliance on external capital. As of mid-2026, bioAffinity's market capitalization had fallen to roughly $2.8-3 million with shares trading near $0.63, down sharply from an IPO-era valuation of approximately $45 million in September 2022 — a decline reflecting persistent losses and investor concern about cash runway even as the underlying CyPath Lung test line shows strong percentage growth off a small base.

Summary Conclusion

bioAffinity Technologies offers a clinically differentiated, IP-protected diagnostic test in a large and growing pulmonary nodule market, and 2025's regulatory resolution around LDT oversight removed a key overhang. However, the company remains a sub-scale, cash-burning micro-cap whose equity has been severely diluted and de-rated, and its investment case now hinges almost entirely on whether CyPath Lung test volumes and reimbursement can scale fast enough to outrun continued capital needs.